Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera…
- M. Pfreundschuh, L. Trümper, +21 authors M. Löffler
- Medicine
- The Lancet. Oncology
- 1 May 2006
BACKGROUND
The role of rituximab in combination with different CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy regimens in young patients with good-prognosis… Expand
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
- A. Scherpereel, P. Astoul, +15 authors W. Weder
- Medicine
- European Respiratory Journal
- 28 August 2009
Malignant pleural mesothelioma (MPM) is a rare tumour but with increasing incidence and a poor prognosis. In 2008, the European Respiratory Society/European Society of Thoracic Surgeons Task Force… Expand
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International…
- M. Pfreundschuh, E. Kuhnt, +18 authors N. Murawski
- Medicine
- The Lancet. Oncology
- 1 October 2011
BACKGROUND
The MInT study was the first to show improved 3-year outcomes with the addition of rituximab to a CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimen in young… Expand
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.
- W. Eberhardt, D. de Ruysscher, +7 authors S. Peters
- Medicine
- Annals of oncology : official journal of the…
- 1 August 2015
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on… Expand
CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells.
- S. Aigner, Z. Sthoeger, +8 authors P. Altevogt
- Biology, Medicine
- Blood
- 1 May 1997
P-selectin (CD62P) is a Ca2+-dependent endogenous lectin that can be expressed by vascular endothelium and platelets. The major ligand for P-selectin on leukocytes is P-selectin glycoprotein ligand-1… Expand
Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.
- O. Gautschi, C. Bigosch, +9 authors A. Ziegler
- Medicine
- Journal of clinical oncology : official journal…
- 15 October 2004
PURPOSE
Circulating cell-free DNA is present in increased amounts in the blood of cancer patients, but the clinical relevance of this phenomenon remains unclear. We conducted a clinical study to… Expand
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.
- K. Kerr, L. Bubendorf, +7 authors E. Felip
- Medicine
- Annals of oncology : official journal of the…
- 1 September 2014
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on… Expand
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.
- J. Vansteenkiste, L. Crinò, +10 authors E. Felip
- Medicine
- Annals of oncology : official journal of the…
- 1 August 2014
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on… Expand
A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy.
- R. Olie, A. P. Simões-Wüst, +4 authors U. Zangemeisterwittke
- Biology, Medicine
- Cancer research
- 1 June 2000
Survivin, an inhibitor of apoptosis protein, deserves attention as a selective target for cancer therapy because it lacks expression in differentiated adult tissues but is expressed in a variety of… Expand
Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: Interleukin‐6 production as a common feature
- D. Schmitter, B. Lauber, B. Fagg, R. Stahel
- Biology, Medicine
- International journal of cancer
- 8 May 1992
Seven mesothelioma cell lines, established from patients with pleural mesothelioma, exhibited substantial heterogeneity regarding in vitro morphology and growth characteristics. Media conditioned by… Expand